Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M63,967Revenue $M21,848Net Margin (%)11.8Z-Score3.8
Enterprise Value $M64,373EPS $1.6Operating Margin %12.0F-Score6
P/E(ttm))27.8Cash Flow Per Share $6.7Pre-tax Margin (%)11.5Higher ROA y-yN
Price/Book2.710-y EBITDA Growth Rate %3.2Quick Ratio1.6Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %-14.5Current Ratio1.9Lower Leverage y-yN
Price/Cash Flow9.8y-y EBITDA Growth Rate %-31.2ROA % (ttm)6.0Higher Current Ratio y-yY
Dividend Yield %1.9Insider Buy (3m)0ROE % (ttm)10.2Less Shares Outstanding y-yY
Payout Ratio %52.0Shares Outstanding M1,502ROI % (ttm)9.7Gross Margin Increase y-yN

Gurus Latest Trades with ABT

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABTJean-Marie Eveillard 2014-06-30 Buy 0.16%$37.02 - $41
($39.24)
$ 42.548%New holding, 1665688 sh.1,665,688
ABTGeorge Soros 2014-06-30 Reduce-0.11%$37.02 - $41
($39.24)
$ 42.548%Reduce -23.73%932,181
ABTGeorge Soros 2014-03-31 Add0.1%$35.85 - $40.12
($38.54)
$ 42.5410%Add 25.97%1,222,181
ABTRay Dalio 2014-03-31 Buy 0.01%$35.85 - $40.12
($38.54)
$ 42.5410%New holding, 17200 sh.17,200
ABTDaniel Loeb 2014-03-31 Sold Out -2.1%$35.85 - $40.12
($38.54)
$ 42.5410%Sold Out0
ABTDaniel Loeb 2013-12-31 Buy 2.1%$33.01 - $38.71
($36.89)
$ 42.5415%New holding, 3250000 sh.3,250,000
ABTMario Gabelli 2013-12-31 Add0.02%$33.01 - $38.71
($36.89)
$ 42.5415%Add 110.21%197,183
ABTRay Dalio 2013-12-31 Sold Out -0.03%$33.01 - $38.71
($36.89)
$ 42.5415%Sold Out0
ABTPRIMECAP Management 2013-09-30 Add0.19%$32.93 - $36.88
($35.12)
$ 42.5421%Add 36.9%16,188,865
ABTRay Dalio 2013-09-30 Buy 0.03%$32.93 - $36.88
($35.12)
$ 42.5421%New holding, 118700 sh.118,700
ABTMason Hawkins 2013-09-30 Reduce-0.12%$32.93 - $36.88
($35.12)
$ 42.5421%Reduce -4.79%13,727,856
ABTJohn Hussman 2013-06-30 Sold Out -0.52%$34.88 - $38.56
($36.68)
$ 42.5416%Sold Out0
ABTVanguard Health Care Fund 2013-06-30 Reduce-0.24%$34.88 - $38.56
($36.68)
$ 42.5416%Reduce -18.79%7,591,400
ABTPRIMECAP Management 2013-03-31 Add0.23%$31.34 - $35.32
($33.84)
$ 42.5426%Add 58.55%11,683,747
ABTGeorge Soros 2013-03-31 Add0.23%$31.34 - $35.32
($33.84)
$ 42.5426%Add 93.84%1,140,752
ABTMario Gabelli 2013-03-31 Add0.01%$31.34 - $35.32
($33.84)
$ 42.5426%Add 40.97%84,215
ABTDaniel Loeb 2013-03-31 Sold Out -1.1%$31.34 - $35.32
($33.84)
$ 42.5426%Sold Out0
ABTJoel Greenblatt 2013-03-31 Sold Out -0.06%$31.34 - $35.32
($33.84)
$ 42.5426%Sold Out0
ABTMeridian Funds 2013-03-31 Sold Out -0.02%$31.34 - $35.32
($33.84)
$ 42.5426%Sold Out0
ABTMason Hawkins 2012-12-31 Add1.43%$14.4 - $16.51
($15.11)
$ 42.54182%Add 85.61%14,754,193
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ABT Jean-Marie Eveillard 2014-06-301,665,6880.110.16New Buy
ABT Ray Dalio 2014-06-3017,70000.01+2.91%
ABT PRIMECAP Management 2014-06-3017,127,0631.140.77+0.23%
ABT Vanguard Health Care Fund 2014-06-307,591,4000.510.82
ABT Dodge & Cox 2014-06-3036,89800-0.14%
ABT Mason Hawkins 2014-06-3013,687,8770.913-0.43%
ABT Mario Gabelli 2014-06-30160,7070.010.03-4.62%
ABT George Soros 2014-06-30932,1810.060.29-23.73%
Premium Most recent portfolio changes are included for Premium Members only!


ABT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Foltz Charles DSenior Vice President 2014-03-03Sell1,588$38.958.42view
Mason Heather LSenior Vice President 2014-03-03Sell2,196$38.958.42view
Blaser Brian JExecutive Vice President 2014-03-03Sell1,441$39.018.25view
ASHLEY RICHARD WExecutive Vice President 2014-03-03Sell2,098$398.28view
ALLEN HUBERT LExecutive Vice President 2014-03-03Sell1,543$39.038.2view
Funck Robert EVice President, Controller 2014-03-03Sell1,413$38.978.37view
FREYMAN THOMAS CExecutive Vice President 2014-03-03Sell2,984$39.18.01view
Contreras JaimeSenior Vice President 2014-03-03Sell8,081$39.377.26view
Warmuth Michael JExecutive Vice President 2014-03-03Sell16,484$39.018.25view
Doyle Katherine C.Senior Vice President 2014-03-03Sell6,639$39.018.25view

Press Releases about ABT :

    Quarterly/Annual Reports about ABT:

    News about ABT:

    Articles On GuruFocus.com
    6 Stocks Currently Trading Below Fair Value Jul 02 2014 
    Why I Bought Baxter International Jun 19 2014 
    Two Stocks On My Watch List For June 2014 May 29 2014 
    Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 
    What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 
    Different Opinions on Bio-Rad Laboratories Apr 03 2014 
    Absolute and Relative Valuation Models Indicate the Same: Abbot Is a Buy Mar 31 2014 
    We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
    Lountzis Asset Management Comments on Abbott Laboratories Mar 21 2014 
    Abbott Capturing Incremental Market Share Mar 18 2014 

    More From Our Partners
    Buyback Mania Inflates 2Q Earnings Growth Aug 14 2014 - FOXBUSINESS

    More From Other Websites
    Abbott Joins Forces with U.S. Department of Defense to Develop Portable Blood Tests for Evaluating... Aug 18 2014
    Abbott, AbbVie Win Dismissal of Suit Over Depakote Marketing Aug 15 2014
    ABBOTT LABORATORIES Financials Aug 12 2014
    Access to Abbott's MitraClip® System Expands in the U.S. with Medicare National Coverage... Aug 12 2014
    Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View Aug 07 2014
    Drug company won't appeal gay rights ruling to top U.S. court Aug 05 2014
    Delamaide: Tax issue shows Congress' failure Aug 05 2014
    ABBOTT LABORATORIES Files SEC form 10-Q, Quarterly Report Aug 05 2014
    [video] Cramer's stocks to watch: KORS Aug 04 2014
    Charles R. Kummeth, the President and CEO of Bio-Techne (TECH), Interviews with The Wall Street... Aug 01 2014
    Can Obamacare case jump right to Supreme Court? Aug 01 2014
    How Obama Could End Walgreen's Tax-Inversion Hopes Jul 28 2014
    3 Stocks Pushing The Health Services Industry Lower Jul 28 2014
    Abbott to Showcase Innovations to Help Labs Solve Health Care Challenges at the American Association... Jul 28 2014
    Top Trade Ideas for the Week of July 28, 2014: The Rest Jul 27 2014
    Obama calls on Congress to end inversion deals, NY Times reports Jul 25 2014
    Did Congress prescribe Obamacare a 'poison pill?' Jul 24 2014
    Abbott Introduces New Similac® Breastfeeding Supplement with DHA, Lutein and Vitamin E Jul 24 2014
    GlaxoSmithKline Slumps: GSK Falls 5.9% in Session Jul 24 2014
    Who gets the last word on Obamacare? Jul 23 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide